Post-Approval U.S. Experience With Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation
- PMID: 27816552
- DOI: 10.1016/j.jacc.2016.10.010
Post-Approval U.S. Experience With Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation
Abstract
Background: Left atrial appendage closure (LAAC) was approved by the U.S. Food and Drug Administration (FDA) as a stroke prevention alternative to warfarin for patients with nonvalvular atrial fibrillation. However, clinical decision-making is confounded by the fact that although LAAC attenuates the anticoagulant-related lifetime risk of bleeding, implantation is associated with upfront complications. Thus, enthusiasm for LAAC as a treatment option has been appropriately tempered, particularly as the therapy is introduced beyond the clinical trial sites into general clinical practice.
Objectives: This study evaluated the acute procedural performance and complication rates for all cases performed in the United States since FDA approval.
Methods: In the absence of a formal national clinical registry since regulatory approval in March 2015, we obtained procedural data on implantation procedures. Every LAAC procedure requires the presence of a manufacturer clinical specialist and for procedural parameter and periprocedural complication data to be collected using a standardized process and forms.
Results: In 3,822 consecutive cases, implantation was successful in 3,653 (95.6%), with a median procedure time of 50 min (range 10 to 210 min). Implanting physicians performing these procedures (n = 382) included 71% new, nonclinical trial implanters, who performed 50% of the procedures. Procedural complication rates included 39 pericardial tamponades (1.02%) (24 treated percutaneously, 12 surgically, and 3 fatal); 3 procedure-related strokes (0.078%); 9 device embolizations (0.24%) (6 requiring surgical removal); and 3 procedure-related deaths (0.078%).
Conclusions: Despite a large fraction of previously inexperienced operators, in the real-world post-FDA approval experience of LAAC, procedural success was high and complication rates were low.
Keywords: Watchman; atrial fibrillation; complications; left atrial appendage closure; stroke.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
Comment in
-
Assessing the Safety of Early U.S. Commercial Application of Left Atrial Appendage Closure.J Am Coll Cardiol. 2017 Jan 24;69(3):262-264. doi: 10.1016/j.jacc.2016.10.019. Epub 2016 Nov 2. J Am Coll Cardiol. 2017. PMID: 27816551 No abstract available.
Similar articles
-
MAUDE Database Analysis of Post-Approval Outcomes following Left Atrial Appendage Closure with the Watchman Device.Am J Cardiol. 2021 Aug 1;152:78-87. doi: 10.1016/j.amjcard.2021.04.015. Epub 2021 Jun 8. Am J Cardiol. 2021. PMID: 34116792
-
The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation.Europace. 2014 Aug;16(8):1131-6. doi: 10.1093/europace/euu038. Epub 2014 Mar 30. Europace. 2014. PMID: 24687964
-
First results of the Brazilian Registry of Percutaneous Left Atrial Appendage Closure.Arq Bras Cardiol. 2017 Nov;109(5):440-447. doi: 10.5935/abc.20170150. Epub 2017 Oct 19. Arq Bras Cardiol. 2017. PMID: 29069203 Free PMC article.
-
The Left Atrial Appendage: Target for Stroke Reduction in Atrial Fibrillation.Methodist Debakey Cardiovasc J. 2015 Apr-Jun;11(2):100-3. doi: 10.14797/mdcj-11-2-100. Methodist Debakey Cardiovasc J. 2015. PMID: 26306127 Free PMC article. Review.
-
Overview of the Food and Drug Administration circulatory system devices panel meetings on WATCHMAN left atrial appendage closure therapy.Am J Cardiol. 2015 Feb 1;115(3):378-84. doi: 10.1016/j.amjcard.2014.11.011. Epub 2014 Nov 12. Am J Cardiol. 2015. PMID: 25579887 Review.
Cited by
-
Left Atrial Appendage Closure: A Single-Center Experience in a Population With a High Prevalence of End-Stage Renal Disease.Cureus. 2024 Sep 12;16(9):e69286. doi: 10.7759/cureus.69286. eCollection 2024 Sep. Cureus. 2024. PMID: 39282495 Free PMC article.
-
Foam-based Left Atrial Appendage Closure (CLAAS) Device: Evaluation in a Chronic Canine Model.J Soc Cardiovasc Angiogr Interv. 2022 Dec 1;2(2):100555. doi: 10.1016/j.jscai.2022.100555. eCollection 2023 Mar-Apr. J Soc Cardiovasc Angiogr Interv. 2022. PMID: 39129799 Free PMC article.
-
Management of complications associated with percutaneous left atrial appendage closure with or without ablation: experience from 512 cases over a 4-year period.Front Cardiovasc Med. 2024 Jul 23;11:1388024. doi: 10.3389/fcvm.2024.1388024. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39108669 Free PMC article.
-
Case Report: Successful retrieval of a migrated left atrial appendage occluder through the synergistic use of a guidewire and a gooseneck snare.Front Cardiovasc Med. 2024 Jun 4;11:1364376. doi: 10.3389/fcvm.2024.1364376. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38903969 Free PMC article.
-
A comparison of conventional and advanced 3D imaging techniques for percutaneous left atrial appendage closure.Front Cardiovasc Med. 2024 Mar 26;11:1328906. doi: 10.3389/fcvm.2024.1328906. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38596690 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
